skip to Main Content

Avalere Deepens Expertise in Medicare and Clinical Decision-Making with 2 New Hires

  • This page as PDF


Matt Kazan and Amy Schroeder bring unique understandings of how policy and clinical data drive healthcare markets.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

Matt Kazan will join the Policy practice as a principal, where he will work with healthcare stakeholders to understand and influence policy that impacts industry, especially in the areas of Medicare Part D, Medicare Advantage, and drug pricing.

Amy Schroeder will be a senior consultant in the Commercialization & Regulatory Strategy practice. She will work with life science companies to drive payer coverage and reimbursement strategies.

“Policy and clinical data continue to drive the evolution of public programs in today’s healthcare market,” said Matt Brow, president at Avalere. “Matt and Amy bring a deep understanding of how policymakers and clinical decision-makers can shape the commercial outlook for healthcare companies.”

About Matt Kazan

Matt Kazan served on the Senate Finance Committee health staff from 2008 to 2019 under Senators Max Baucus (D-MT) and Ron Wyden (D-OR). He was most recently a senior health policy adviser to ranking member Wyden and worked on policy issues related to Medicare Advantage, Medicare Part D, chronic disease, and Medicare and Medicaid program integrity. Some of the legislation that he worked on included the Affordable Care Act, the Bipartisan Budget Act of 2018, and the American Recovery and Reinvestment Act.

About Amy Schroeder

Amy Schroeder brings more than 30 years of healthcare experience to Avalere with a primary focus on understanding how clinical data impacts payer coverage and reimbursement. She worked with the United States Pharmacopeia (USP) to help create USP guidelines to guide Part D plans in developing and maintaining their drug formularies. She also serves as a patient advocate on the Medicare Evidence Development & Coverage Advisory Committee and on the editorial board of the Journal of Clinical Pathways. She is also the only pharmacist who has contributed to the content of 3 clinical drug compendia: United States Pharmacopeia Drug Information, American Hospital Formulary Service Drug Information, and the National Comprehensive Cancer Network Drugs & Biologics Compendium, which is recognized by the Centers for Medicare & Medicaid Services and commercial payers.

To receive Avalere updates, connect with us.

From beginning to end, our team synergy
produces measurable results. Let's work together.
Back To Top